Not Your Grandparents’ Drugs: How Approved Drugs Have Evolved Since the 70’s
Other articles you may be interested in
Leaving Academia to Discover a Billion-Dollar Drug: Reflections from a Thirty-Year Path to Momelotinib’s Approval
Momelotinib is a JAK inhibitor approved by the FDA in September 2023 for treating myelofibrosis. Last year, the molecule’s co-inventors, Andrew Wilks and Christopher Burns, gave a Drug Hunter Flash talk about the development of this drug with a fascinating mechanism of action.
In celebration of the molecule’s advancement, here we recap their brilliant story, including Wilks’ discovery of the JAK kinases and how he gave them their name, and the long, sometimes fraught journey of momelotinib through several companies before its acquisition and commercialization by GSK.
MYT1, Pan-RAF, Pan-RAS and More: Dec. ’23 Compound Collection
The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >60 additional molecules that were of interest in December 2023 along with highlights from some of the team’s favorites in the article.
Drug-Induced Liver Injury: A Medicinal Chemist’s Perspective
DILI is a leading cause of acute liver failure, accounting for half of these cases and often resulting in drug withdrawals. Understanding and managing DILI risk as a medicinal chemist involves exploring the intricate interplay among properties and structural features. In this article, we provide a medicinal chemist's perspective on the current understanding of DILI mechanisms, highlight cutting-edge assay developments for a holistic assessment, and discuss strategies for predicting DILI risks.
Quality is Key: Turnkey AI Solution Powered by Robust Big Data
Imagine having access to an almost infinite amount of chemical space that could include the next blockbuster medicine waiting to be discovered. The challenge for medicinal chemists is balancing the exploration of this vast space in early drug discovery with the need for focused exploration in later stages. This article explores the genesis of a new AI-powered drug design tool, AIDDISON™ from MilliporeSigma, and how this platform can benefit discovery teams around the world.
2023 Molecules of the Year: Nominate!
The final set of Molecules of the Month for 2023 is out, and now it’s time to nominate your favorite molecules for 2023’s Molecules of the Year! Nominees should have either been first disclosed in 2023 or had a major new update in 2023 (e.g. clinical trial readout, publication, business transaction, approval). The molecule must have a [...]
